Krsnaa Diagnostics (KRSNAA) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue grew 10% YoY to INR 1,745 million, with net profit up 50% YoY to INR 194 million, driven by strong volumes and operational efficiency.

• Nine-month FY25 revenue rose 17% YoY to INR 5,311 million; EBITDA up 39% YoY to INR 1,416 million, margin at 27%.

• Net profit for nine months reached INR 569 million, matching the previous full year, up 49% YoY.

• Retail (B2C) segment launched in four states, with 284 new collection centers added and plans for significant expansion.

• Board approved unaudited results for Q3 and nine months ended December 31, 2024; new Managing Director appointed.

Financial highlights

• Q3 EBITDA at INR 466 million, margin 27%; net profit INR 194 million, up 50% YoY.

• Diluted EPS for nine months at INR 17.26, up 47% YoY; Q3 EPS at INR 5.9, up 48% YoY.

• Consolidated revenue for Q3 FY25: INR 1,745.12 million; net profit: INR 194.15 million.

• Other income driven by interest from fixed deposits and capital gains.

• Cost of material consumed: 23% of revenue in Q3 FY25; employee benefits: 20% of revenue.

Outlook and guidance

• Q4 expected to show growth as delayed projects come online; larger benefits anticipated from Q1 FY26.

• Management remains positive on achieving 25% annual revenue growth guidance, with strategic initiatives underway.

• Retail segment expected to contribute significantly in FY26 and beyond, targeting at least 500 touchpoints next year.

• Focus on expanding B2B partnerships to 1,000 by FY26 and tapping underpenetrated markets.

• Management believes ongoing tax proceedings will not have a material impact on financials.